A meta-analysis of 66 studies on bone mineral density (BMD) and 23 studies on fractures found that oral corticosteroid use is associated with reduced BMD and increased fracture risk. The risk of fracture increases rapidly after starting corticosteroid therapy and decreases after stopping. The risk is independent of age, gender, and underlying disease. Daily doses above 5 mg of prednisolone or equivalent significantly reduce BMD and increase fracture risk. Preventive measures are recommended for patients on high-dose corticosteroids. The study highlights the importance of early intervention to prevent corticosteroid-induced osteoporosis. The relationship between corticosteroid dose and BMD loss was strong, with cumulative dose showing a significant correlation with BMD loss. Daily dose was also associated with increased fracture risk, though the relationship was weaker. The study found that bone loss occurs rapidly after starting corticosteroid therapy and slows over time. Bone loss was more pronounced in trabecular bone than cortical bone. The risk of fracture was higher in patients with corticosteroid-induced osteoporosis compared to those with postmenopausal osteoporosis, even at similar BMD levels. The study also found that bone loss due to corticosteroids is primarily due to trabecular thinning rather than other mechanisms. The effects of corticosteroids on bone are reversible after discontinuation. The study suggests that preventive measures should be implemented for patients on corticosteroids at doses above 5 mg/day. The results indicate that corticosteroid-induced osteoporosis is a significant health issue that requires early intervention. The study also found that the risk of fracture is higher in patients with certain underlying conditions. The study concludes that corticosteroid-induced osteoporosis is a major concern and that preventive measures are essential for patients on long-term corticosteroid therapy.A meta-analysis of 66 studies on bone mineral density (BMD) and 23 studies on fractures found that oral corticosteroid use is associated with reduced BMD and increased fracture risk. The risk of fracture increases rapidly after starting corticosteroid therapy and decreases after stopping. The risk is independent of age, gender, and underlying disease. Daily doses above 5 mg of prednisolone or equivalent significantly reduce BMD and increase fracture risk. Preventive measures are recommended for patients on high-dose corticosteroids. The study highlights the importance of early intervention to prevent corticosteroid-induced osteoporosis. The relationship between corticosteroid dose and BMD loss was strong, with cumulative dose showing a significant correlation with BMD loss. Daily dose was also associated with increased fracture risk, though the relationship was weaker. The study found that bone loss occurs rapidly after starting corticosteroid therapy and slows over time. Bone loss was more pronounced in trabecular bone than cortical bone. The risk of fracture was higher in patients with corticosteroid-induced osteoporosis compared to those with postmenopausal osteoporosis, even at similar BMD levels. The study also found that bone loss due to corticosteroids is primarily due to trabecular thinning rather than other mechanisms. The effects of corticosteroids on bone are reversible after discontinuation. The study suggests that preventive measures should be implemented for patients on corticosteroids at doses above 5 mg/day. The results indicate that corticosteroid-induced osteoporosis is a significant health issue that requires early intervention. The study also found that the risk of fracture is higher in patients with certain underlying conditions. The study concludes that corticosteroid-induced osteoporosis is a major concern and that preventive measures are essential for patients on long-term corticosteroid therapy.